JP2013541586A5 - - Google Patents

Download PDF

Info

Publication number
JP2013541586A5
JP2013541586A5 JP2013537756A JP2013537756A JP2013541586A5 JP 2013541586 A5 JP2013541586 A5 JP 2013541586A5 JP 2013537756 A JP2013537756 A JP 2013537756A JP 2013537756 A JP2013537756 A JP 2013537756A JP 2013541586 A5 JP2013541586 A5 JP 2013541586A5
Authority
JP
Japan
Prior art keywords
cancer
pyrazin
yloxy
pyrazol
piperidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013537756A
Other languages
English (en)
Japanese (ja)
Other versions
JP5792316B2 (ja
JP2013541586A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/058692 external-priority patent/WO2012064548A1/en
Publication of JP2013541586A publication Critical patent/JP2013541586A/ja
Publication of JP2013541586A5 publication Critical patent/JP2013541586A5/ja
Application granted granted Critical
Publication of JP5792316B2 publication Critical patent/JP5792316B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013537756A 2010-11-08 2011-11-01 Chk1を阻害するのに有用な化合物 Active JP5792316B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41113710P 2010-11-08 2010-11-08
US61/411,137 2010-11-08
PCT/US2011/058692 WO2012064548A1 (en) 2010-11-08 2011-11-01 Compounds useful for inhibiting chk1

Publications (3)

Publication Number Publication Date
JP2013541586A JP2013541586A (ja) 2013-11-14
JP2013541586A5 true JP2013541586A5 (https=) 2014-12-18
JP5792316B2 JP5792316B2 (ja) 2015-10-07

Family

ID=45044707

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013537756A Active JP5792316B2 (ja) 2010-11-08 2011-11-01 Chk1を阻害するのに有用な化合物

Country Status (22)

Country Link
US (1) US9067920B2 (https=)
EP (1) EP2638033B1 (https=)
JP (1) JP5792316B2 (https=)
KR (1) KR101533166B1 (https=)
CN (1) CN103180311B (https=)
AR (1) AR083575A1 (https=)
AU (1) AU2011326230B2 (https=)
BR (1) BR112013010009B1 (https=)
CA (1) CA2816944C (https=)
DK (1) DK2638033T3 (https=)
EA (1) EA022096B1 (https=)
ES (1) ES2541414T3 (https=)
HR (1) HRP20150530T1 (https=)
JO (1) JO3145B1 (https=)
ME (1) ME02119B (https=)
MX (1) MX2013005181A (https=)
PL (1) PL2638033T3 (https=)
PT (1) PT2638033E (https=)
RS (1) RS54012B1 (https=)
SI (1) SI2638033T1 (https=)
TW (1) TWI501956B (https=)
WO (1) WO2012064548A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201402277D0 (en) 2014-02-10 2014-03-26 Sentinel Oncology Ltd Pharmaceutical compounds
HRP20220351T1 (hr) 2016-02-04 2022-05-13 Pharmaengine, Inc. 3,5-disupstituirani pirazoli korisni kao inhibitori kinaze 1 kontrolne točke (chk1), i njihove pripreme i primjene
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
CN112457306A (zh) 2019-09-06 2021-03-09 上海瑛派药业有限公司 3,5-二取代吡唑化合物作为激酶抑制剂及其应用
AU2021389190A1 (en) 2020-11-30 2023-06-29 Sumitomo Pharma Co., Ltd. 5-heteroaryl-1h-pyrazol-3-amine derivative
US11564920B2 (en) 2020-11-30 2023-01-31 Sumitomo Pharma Co., Ltd. 5-heteroaryl-1H-pyrazol-3-amine derivative
US11932648B2 (en) 2021-06-28 2024-03-19 Blueprint Medicines Corporation CDK2 inhibitors
US20250129049A1 (en) * 2021-12-24 2025-04-24 Sumitomo Pharma Co., Ltd. 1h-pyrazole-3-amine derivative having bicyclic backbone
US20250352541A1 (en) * 2022-05-27 2025-11-20 Sumitomo Pharma Co., Ltd. Therapeutic for cancer refractory to immune checkpoint inhibitor
TW202442234A (zh) * 2023-04-14 2024-11-01 美商纜圖藥品公司 Cdk2抑制劑

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06000933A (es) * 2003-07-25 2006-03-30 Pfizer Compuestos de aminopirazol y uso como inhibidores de chk1.
BRPI0418351A (pt) * 2004-01-05 2007-05-08 Astrazeneca Ab composto ou um sal farmaceuticamente aceitável do mesmo, métodos de limitar a proliferação celular em um humano ou animal, de tratamento de um humano ou animal sofrendo de cáncer, de tratamento de profilaxia de cáncer, de tratamento de um humano ou animal sofrendo de uma doença neoplásica, de tratamento de um humano ou animal sofrendo de uma doença prolifetativa de tratamento de cáncer, para o tratamento de infecções associadas com cáncer, para o tratamento profilático de infecções associadas com cáncer, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, método de inibir a chk1 quinase, e, processo para a preparação de um composto ou um sal farmaceuticamente aceitável do mesmo
EA011671B1 (ru) 2004-06-04 2009-04-28 Арена Фармасьютикалз, Инк. Замещенные производные арила и гетероарила в качестве модуляторов метаболизма и для профилактики и лечения связанных с ним расстройств
CN101218229A (zh) * 2005-05-05 2008-07-09 阿斯利康(瑞典)有限公司 吡唑基-氨基取代的嘧啶及其在癌症治疗中的应用
AU2006258101A1 (en) * 2005-06-09 2006-12-21 Merck Sharp & Dohme Corp. Inhibitors of checkpoint kinases
WO2008117050A1 (en) * 2007-03-27 2008-10-02 Astrazeneca Ab Pyrazolyl-amino-substituted pyrazines and their use for the treatment of cancer
PA8850801A1 (es) * 2008-12-17 2010-07-27 Lilly Co Eli Compuestos útiles para inhibir chk1

Similar Documents

Publication Publication Date Title
JP2013541586A5 (https=)
ME02119B (me) Spojevi korisni za inhibiranje chk1
HRP20130167T1 (hr) Spojevi korisni za inhibiranje chk1
PH12021550418A1 (en) Macrocycles with hetrocyclic p2` groups as factor xia inhibitors
RU2015154275A (ru) Комбинации антитела против pd-l1 и ингибитора mek и/или ингибитора braf
JP2020517616A5 (https=)
MX2014012695A (es) Derivados de isoindolona.
CN107548391A (zh) 嘧啶或吡啶类化合物、其制备方法和医药用途
MX2014012741A (es) Derivados de imidazotiadiazol e imidazopirazina como inhibidores del receptor 4 activado de proteasa (par4) para tratamiento de agregacion plaquetaria.
TN2017000511A1 (en) New hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them.
JP2017509586A5 (https=)
MY192521A (en) Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
MX2014012454A (es) Derivados de imidazotiadiazol como inhibidores del receptor 4 activado de proteasa (par4) para el tratamiento de agregacion plaquetaria.
NZ626942A (en) New indolizine derivatives, method for preparing same and pharmaceutical compositions containing same
WO2014152389A8 (en) Imaging agent for detection of diseased cells
MX2015012432A (es) Inhibidores piridinicos de la cinasa cdk9.
HK1208681A1 (en) Pyridinone and pyridazinone derivatives
ME02663B (me) Derivati benzimidazola kao inhibitori pi3 kinaze
JO3115B1 (ar) مركبات بيريدازينون واستخدامها كمثبطات daao
GEP201706778B (en) Pyridinyl and fused pyridinyl triazolone derivatives
JP2009536652A5 (https=)
UY30310A1 (es) Derivados 2-azetidinona, sales, solvatos, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones
JP2017519027A5 (https=)
JP2016507575A5 (https=)
JP2017532360A5 (https=)